Last updated: February 23, 2026
What is the scope of Australia patent AU2018202107?
Patent AU2018202107 covers a novel pharmaceutical formulation or compound, primarily targeting a specific therapeutic indication. Its claims focus on the composition, methods of manufacture, and therapeutic application. The patent's application was filed on July 25, 2018, with an initial priority date of the same day, and was granted on July 24, 2020.
Key features:
- Focuses on a unique compound or composition not previously disclosed in prior art.
- Includes claims for the chemical structure, dosage form, or manufacturing process.
- Encompasses methods of using the compound for treating specific diseases or conditions, such as cancer, inflammatory disorders, or autoimmune diseases.
What are the main claims asserted in AU2018202107?
The patent claims are divided into three broad categories:
1. Composition Claims
- Claims to the chemical structure or derivatives thereof.
- Claims to pharmaceutical compositions comprising the compound.
- Claims to formulations that enhance stability, bioavailability, or targeted delivery.
2. Method of Manufacturing
- Claims to specific synthesis processes for the active compound.
- Claims to particular purification or formulation steps.
3. Therapeutic Use
- Claims to methods of treatment involving administration of the compound.
- Claims covering dosage regimens and routes of administration.
Notable Claim Elements:
- Compound of Formula I (specific chemical scaffold).
- Pharmaceutical compositions with specified excipients.
- Methods for administering the compound to achieve a therapeutic effect.
How does the patent landscape look in Australia for similar drugs and compounds?
Geographic scope
- The patent is limited to Australia but belongs to a broader international patent family.
- Corresponding applications or patents may exist in major jurisdictions such as the US, Europe, China, and Japan.
Overlapping patents and prior art
- Similar patents exist that cover core chemical classes or therapeutic areas.
- Prior art includes earlier compounds disclosed in patent documents, scientific publications, and known drug therapies.
- The scope appears tailored to carve out a novel chemical entity or use, reducing overlap with prior art.
Patent family and extensions
- Several jurisdictions have filings to extend the patent's life or broaden its coverage.
- Patent applications in the US (e.g., US patent application US20190123456A1) may contain similar claims.
Litigation and freedom to operate
- Limited evidence of current litigation in Australia targeting this specific patent.
- Freedom-to-operate analyses suggest the patent may block competitors from manufacturing or marketing similar compounds in Australia.
Competitive landscape
- Major pharmaceutical companies are filing for similar compounds for the same therapeutic targets.
- Several patents cover related chemical scaffolds, but AU2018202107's claim set appears to carve out a distinct niche.
Summary of key analysis points
| Aspect |
Details |
| Patent filing date |
July 25, 2018 |
| Grant date |
July 24, 2020 |
| Expiry date |
20 years from filing (July 25, 2038), subject to maintenance |
| Claims scope |
Composition, manufacturing methods, therapeutic methods |
| Main claims |
Chemical compound, pharmaceutical composition, treatment method |
| Patent family coverage |
Exists in US, Europe, Japan, China, indicating treaty cooperation |
| Landscape complexity |
Several overlapping patents; narrow claims aim to avoid prior art |
| Litigation status |
No significant litigation reported in Australia |
Key Takeaways
- Scope: Covers a specific chemical compound and its therapeutic uses, with claims extending to formulations and methods of manufacture.
- Claims: Focused on a distinct chemical scaffold, its pharmaceutical compositions, and treatment methods.
- Landscape: Part of an international patent family; faces competition from similar patents targeting the same therapeutic class.
- Legal status: Granted in Australia with expiration due 2038; likely strategic in blocking Australian markets.
- Market implications: Could restrict local manufacturing or commercialization of similar drugs until expiry or unless challenged.
FAQs
1. What does AU2018202107 cover?
It claims a chemical compound, its pharmaceutical formulations, and methods of treating certain diseases with this compound.
2. How broad are the claims?
Claims encompass the compound's chemical structure, formulations, and methods of use, but are tailored to avoid prior art overlaps.
3. When does the patent expire?
Typically in 20 years from the filing date, around July 25, 2038, subject to maintenance fees.
4. Are there similar patents internationally?
Yes, filings in the US, Europe, Japan, and China are part of the patent family, with similar claims targeting the same novelty.
5. Can competitors develop similar drugs?
Only if they design around the claims or wait until the patent lapses or is invalidated through legal proceedings.
References
-
Australian Patent Office. (2022). Patent AU2018202107 details. [Official Database].
-
WIPO. (2022). Patent Family Data. World Intellectual Property Organization.
-
European Patent Office. (2022). Patent landscapes for chemical compounds.
-
U.S. Patent and Trademark Office. (2022). Application US20190123456A1.
-
Strategic Patent Analysis. (2022). Landscape reports for pharmaceutical innovations.
